R. J. Harley

Learn More
BACKGROUND AND OBJECTIVES In Australia, the risk of transfusion-transmitted malaria is managed through the identification of 'at-risk' donors, antibody screening enzyme-linked immunoassay (EIA) and, if reactive, exclusion from fresh blood component manufacture. Donor management depends on the duration of exposure in malarious regions (>6 months: 'Resident',(More)
1940 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 20, No. 11, November 2014 in previously healthy white patients from Germany differ from previously published cases. These 2 patients were not of Asian ethnicity and had no travel history, no contact with persons in a high-risk group (10), and no common risk factors such as malignancy (8); however, 1(More)
BACKGROUND In many developed countries hepatitis E virus (HEV) infections have occurred predominantly in travellers to countries endemic for HEV. HEV is a potential threat to blood safety as the virus is transfusion-transmissible. To minimise this risk in Australia, individuals diagnosed with HEV are deferred. Malarialdeferrals, when donors are restricted(More)
BACKGROUND Leptospirosis is one of the most common bacterial zoonoses worldwide, and clinical manifestations range from asymptomatic infection to acute febrile illness, multi-organ failure and death. Asymptomatic, acute bacteraemia in a blood donor provides a potential for transfusion-transmission, although only a single such case from India has been(More)
Dissociated newborn rat superior cervical ganglion neurons in culture without exogenous nerve growth factor survive and extend processes on a monolayer of rat heart ventricular cells. An increase in the contraction rate of the heart cells was observed in 83% of the co-cultures treated with 5 X 10(-6) M tyramine. No increase was seen in heart cell cultures(More)
Dengue viruses (DENV 1-4) are a risk to transfusion safety, with several transfusion-transmitted (TT) cases reported globally. DENV 1-4 are endemic in over 100 countries, with seasonal outbreaks occurring in northeastern Australia. To mitigate TT-DENV risk in Australia, fresh blood components are not manufactured from donors returning from any area(More)
Two Australian blood donors were diagnosed with relapsing Plasmodium vivax malaria 5 and 15 months, respectively, after their most recent travel to a malaria-endemic country. Common features included travel to Papua New Guinea (specifically, the Kokoda Trail); full compliance with recommended malaria chemoprophylaxis; and negative results on malaria(More)